← Leaderboards
Robert Newton Brey
Dor Biopharma, Inc.
$21,072,952
Attributed
$21,072,952
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3.3M · FY2005–13$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$21,072,952 · 5
FDA$0 · 1
By mechanism
U01$14,019,189 · 2
UC1$6,433,316 · 1
R43$620,447 · 2
R01$0 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Ricin”
- Alessandro Sette · La Jolla Institute For Immunology$22,115,370
- David Heimbrook · Leidos Biomedical Research, Inc.$21,781,988
- Robert Brey · Soligenix, Inc.$21,224,085
- Ellen S Vitetta · University Of Texas Sw Med Ctr/Dallas$9,192,263
- Nilgun E Tumer · Rutgers The St Univ Of Nj New Brunswick$9,017,966
- Jolie Colomb · Nysdoh/Health Research, Inc.$7,627,823
Research focus
RicinImmune ResponseVaccinesAerosolsAntigensToxicologySaltsUnited States National Institutes Of HealthPreventIntramuscular InjectionsResponseProtein DegradationSodium ChlorideDoseCyclic GmpClinical ResearchImmunogenicityFreezingAdjuvantClinical TrialsOryctolagus CuniculusPre-ClinicalAluminumProteins
Grant awards (12)
Development of stable and rapidly acting adjuvanted vaccines for biodefense$1,182,630
U01 · FY2013 · AI · contact PI
Development of stable and rapidly acting adjuvanted vaccines for biodefense$1,341,348
U01 · FY2012 · AI · contact PI
Development of stable and rapidly acting adjuvanted vaccines for biodefense$3,333,529
U01 · FY2011 · AI · contact PI
Development of stable and rapidly acting adjuvanted vaccines for biodefense$1,891,104
U01 · FY2010 · AI · contact PI
Development of stable and rapidly acting adjuvanted vaccines for biodefense$1,305,761
U01 · FY2009 · AI · contact PI
Continued Development of a Recombinant Vaccine (RivaxTM) against Ricin Toxin$687,326
U01 · FY2008 · AI · contact PI
Continued Development of a Recombinant Vaccine (RivaxTM) against Ricin Toxin$1,802,850
U01 · FY2007 · AI · contact PI
Continued Development of a Recombinant Vaccine (RivaxTM) against Ricin Toxin$2,474,641
U01 · FY2006 · AI · contact PI
Development of a mucosally administered trivalent serotype A,B, E botulinum va$470,535
R43 · FY2006 · AI · contact PI
ORAL BDP FOR THE TREATMENT OF GI GVHD$0
R01 · FY2005 · FD
DEVELOPMENT OF A RECOMBINANT VACCINE FOR RICIN TOXIN$6,433,316
UC1 · FY2004 · AI
MICROSPHERE VACCINE AGAINST AEROSOLIZED RICIN TOXIN$149,912
R43 · FY2003 · AI